Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Triclav is a combination antibiotic consisting of ticarcillin, a semi-synthetic penicillin, and clavulanic acid, a beta-lactamase inhibitor. Ticarcillin acts by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), while clavulanic acid irreversibly binds to and inactivates beta-lactamase enzymes produced by bacteria, thereby extending the spectrum of ticarcillin to include many beta-lactamase-producing organisms. It is primarily used for the treatment of serious infections caused by susceptible strains of bacteria, including septicemia, lower respiratory tract infections, and intra-abdominal infections. In the Philippines, it is distributed by The Cathay Drug Company.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ticarcillin + clavulanic acid (GSK).